444 related articles for article (PubMed ID: 28161830)
1. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
2. Combined VEGF/PDGF inhibition using axitinib induces αSMA expression and a pro-fibrotic phenotype in human pericytes.
Siedlecki J; Asani B; Wertheimer C; Hillenmayer A; Ohlmann A; Priglinger C; Priglinger S; Wolf A; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1141-1149. PubMed ID: 29721663
[TBL] [Abstract][Full Text] [Related]
3. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway.
Asani B; Siedlecki J; Wertheimer C; Liegl R; Wolf A; Ohlmann A; Priglinger S; Priglinger C
BMC Ophthalmol; 2022 Mar; 22(1):138. PubMed ID: 35337287
[TBL] [Abstract][Full Text] [Related]
5. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
Kang S; Roh CR; Cho WK; Park KC; Yang KJ; Choi HS; Kim SH; Roh YJ
Curr Eye Res; 2013 Jan; 38(1):119-27. PubMed ID: 23013553
[TBL] [Abstract][Full Text] [Related]
7. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling.
Liu Y; Feng M; Cai J; Li S; Dai X; Shan G; Wu S
Exp Eye Res; 2021 Mar; 204():108446. PubMed ID: 33476605
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
[TBL] [Abstract][Full Text] [Related]
9. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM; Ciulla TA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
[TBL] [Abstract][Full Text] [Related]
10. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
[TBL] [Abstract][Full Text] [Related]
11. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Kernt M; Thiele S; Liegl RG; Kernt B; Eibl K; Haritoglou C; Ulbig MW; Kampik A
Growth Factors; 2012 Feb; 30(1):49-61. PubMed ID: 22168366
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
13. PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently.
Zheng L; Zhao C; Du Y; Lin X; Jiang Y; Lee C; Tian G; Mi J; Li X; Chen Q; Ye Z; Huang L; Wang S; Ren X; Xing L; Chen W; Huang D; Gao Z; Zhang S; Lu W; Tang Z; Wang B; Ju R; Li X
Oncotarget; 2016 Nov; 7(47):77902-77915. PubMed ID: 27788490
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
Guo P; Hu B; Gu W; Xu L; Wang D; Huang HJ; Cavenee WK; Cheng SY
Am J Pathol; 2003 Apr; 162(4):1083-93. PubMed ID: 12651601
[TBL] [Abstract][Full Text] [Related]
15. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
Hollanders K; Van Bergen T; Kindt N; Castermans K; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1335-48. PubMed ID: 25626969
[TBL] [Abstract][Full Text] [Related]
16. Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration.
Wang WQ; Wang FH; Qin WX; Liu HY; Lu B; Chung C; Zhu J; Gu Q; Shi W; Wen C; Wu F; Zhang K; Sun XD
Mol Pharm; 2016 Sep; 13(9):2881-90. PubMed ID: 27089240
[TBL] [Abstract][Full Text] [Related]
17. A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytes.
Shen Y; Xu M; Ren L; Li X; Han X; Cao X; Yao J; Yan B
Sci Rep; 2023 Jun; 13(1):10439. PubMed ID: 37369771
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.
Jo N; Mailhos C; Ju M; Cheung E; Bradley J; Nishijima K; Robinson GS; Adamis AP; Shima DT
Am J Pathol; 2006 Jun; 168(6):2036-53. PubMed ID: 16723717
[TBL] [Abstract][Full Text] [Related]
19. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
[TBL] [Abstract][Full Text] [Related]
20. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
Chaoran Z; Zhirong L; Gezhi X
Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1493-501. PubMed ID: 21574021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
